184 related articles for article (PubMed ID: 38585981)
1. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
Res Sq; 2024 Mar; ():. PubMed ID: 38585981
[TBL] [Abstract][Full Text] [Related]
2. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863
[TBL] [Abstract][Full Text] [Related]
3. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.
Takeshita T; Asaoka M; Katsuta E; Photiadis SJ; Narayanan S; Yan L; Takabe K
Am J Transl Res; 2019; 11(10):6507-6521. PubMed ID: 31737202
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of stem cell surface markers CD133, CD24, and CD44 in colorectal cancer.
Huang JL; Oshi M; Endo I; Takabe K
Am J Cancer Res; 2021; 11(10):5141-5154. PubMed ID: 34765317
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
Wu R; Oshi M; Asaoka M; Yan L; Benesch MGK; Khoury T; Nagahashi M; Miyoshi Y; Endo I; Ishikawa T; Takabe K
Ann Surg; 2023 Oct; 278(4):587-597. PubMed ID: 37318852
[TBL] [Abstract][Full Text] [Related]
7. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
8. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
9. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K
Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer.
Liu Q; Huang S; Desautels D; McManus KJ; Murphy L; Hu P
Comput Struct Biotechnol J; 2023; 21():2940-2949. PubMed ID: 37216014
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
13. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
14. High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive/HER2-Negative Breast Cancer.
Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371179
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.
Atallah NM; Haque M; Quinn C; Toss MS; Makhlouf S; Ibrahim A; Green AR; Alsaleem M; Rutland CS; Allegrucci C; Mongan NP; Rakha E
Eur J Cancer; 2023 Dec; 195():113371. PubMed ID: 37897865
[TBL] [Abstract][Full Text] [Related]
16. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
17. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
Santarpia L; Iwamoto T; Di Leo A; Hayashi N; Bottai G; Stampfer M; André F; Turner NC; Symmans WF; Hortobágyi GN; Pusztai L; Bianchini G
Oncologist; 2013; 18(10):1063-73. PubMed ID: 24072219
[TBL] [Abstract][Full Text] [Related]
18. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
[TBL] [Abstract][Full Text] [Related]
19. High
Nelson ED; Benesch MG; Wu R; Ishikawa T; Takabe K
Am J Cancer Res; 2024; 14(1):227-242. PubMed ID: 38323277
[TBL] [Abstract][Full Text] [Related]
20. A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.
Hamy AS; Bonsang-Kitzis H; Lae M; Moarii M; Sadacca B; Pinheiro A; Galliot M; Abecassis J; Laurent C; Reyal F
PLoS One; 2016; 11(12):e0167397. PubMed ID: 28005906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
